This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

This study has been terminated.
(Slow accrual)
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT01696045
First received: September 26, 2012
Last updated: August 24, 2016
Last verified: August 2016
  Purpose
The purpose of the study is to comply with the Pediatric Investigation Plan requirements of Ipilimumab

Condition Intervention Phase
Malignant Melanoma Biological: Ipilimumab Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma

Resource links provided by NLM:


Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Overall Survival Rate at 1-Year [ Time Frame: Up to 1 year after last patient first treatment (LPFT) ]
    Overall Survival Rate at 1-Year is defined as the probability that a subject is alive at one year following start of treatment. The time frame for this endpoint is from Day 1 of first patient first treatment to Day 365 from the last patient first treatment

  • Severe Immune-mediated Adverse Events (imARs) rate [ Time Frame: Up to 1 year after LPFT ]
    Severe imARs rate is defined as the total number of treated subjects who were categorized as having a grade 3 or worse imAR divided by the total number of treated subjects. The time frame for this endpoint is from Day 1 of first patient first treatment to Day 365 from the last patient first treatment


Secondary Outcome Measures:
  • Disease Control Rate (DCR) [ Time Frame: Up to 1 year after LPFT ]
    DCR is defined as the total number of treated subjects with a best overall response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD), divided by the total number of treated subjects. The time frame for this endpoint is from Day 1 of first patient first treatment to Day 365 from the last patient first treatment

  • Progression-Free Survival (PFS) [ Time Frame: Up to 1 year after LPFT ]
    PFS is defined for each subject as the time from start of ipilimumab treatment to progression or death, whichever occurs first. The time frame for this endpoint is from Day 1 of first patient first treatment to Day 365 from the last patient first treatment

  • Best Overall Response Rate (BORR) [ Time Frame: Up to 1 year after LPFT ]
    BORR is defined as the total number of treated subjects with a best overall response of CR or PR, divided by the total number of treated subjects. The time frame for this endpoint is from Day 1 of first patient first treatment to Day 365 from the last patient first treatment

  • Overall Survival [ Time Frame: Up to 1 year after LPFT ]

Enrollment: 12
Study Start Date: November 2012
Study Completion Date: July 2016
Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ipilimumab
Ipilimumab 3 mg/Kg solution by Intravenous (IV) once every 3 weeks for 4 doses, then every 12 weeks until progression of disease or unacceptable toxicity
Biological: Ipilimumab
Other Names:
  • Yervoy
  • BMS- 734016

  Eligibility

Ages Eligible for Study:   12 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

  • 12 < 18 years of age
  • Previously treated or untreated, unresectable Stage III or Stage IV malignant melanoma
  • Karnofsky Performance Status (KPS) or Lansky Score ≥ 50

Exclusion Criteria:

  • Primary Ocular Melanoma
  • Prior therapy with a Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) or Programmed death- 1 (PD-1) antagonist, or Programmed cell death- ligand 1 (PD-L1) or CD137 agonists
  • Symptomatic brain metastases
  • History of autoimmune diseases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01696045

  Show 30 Study Locations
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT01696045     History of Changes
Other Study ID Numbers: CA184-178
2012-002249-39 ( EudraCT Number )
Study First Received: September 26, 2012
Last Updated: August 24, 2016

Additional relevant MeSH terms:
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 23, 2017